Chronic Eosinophilic Leukemia/ Hypereosinophilic Syndrome

摘要: Although HES and CEL are indeed rare clinical entities, interest in these disorders has been reborn due to a renaissance uncovering the biologic basis of previously idiopathic cases. Unmasking molecular for such cases has, turn, led development semimolecular classification schemes categorizing patients based on recurrent genetic alterations, usually related constitutively activated tyrosine kinases. In increasing sophistication unmasking underpinnings eosinophilia heretofore classified as now permits rationale use biologically targeted therapies imatinib mesylate recombinant anti-IL-5 antibody. The WHO convenes 2007 review prior diagnostic criteria both CEL. It will be see how new information becomes integrated with traditional histopathologic establishing practical road map clinicians who treat diseases.